Previous 10 | Next 10 |
MOUNTAIN VIEW, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's third quarter 2021 financial results will be released after market close on Tuesday, November 9, 2021. ChemoCentryx executive management will host a conference cal...
Growth stocks can be a thing of beauty. These types of equities can linger in your portfolio for years without doing much. Then one day, they can double or even triple in value within a matter of hours. The trick, if you will, is to suss out growth stocks that won't rot on the vine, so to s...
4 Trending Biotech Stocks To Watch Amid AstraZeneca’s News While investors eagerly await the beginning of the third-quarter earnings season, biotech stocks continue to gain traction. For the most part, this area of the stock market today has plenty to offer investors now....
Appointment Brings More than 20 Years of Drug Development Experience as Company Launches First Product SAN CARLOS, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the appointment of Rita I. Jain, M.D., as Executive Vice President, Chie...
Shares of ChemoCentryx (NASDAQ: CCXI) soared 96% on Friday after the biopharmaceutical company received Food and Drug Administration approval for its treatment for a rare autoimmune disease. ChemoCentryx's orally administered drug, avacopan, will be sold under the brand name...
While stocks finished fractionally lower on Friday after a disappointing payroll report, oil prices continued their steady climb, driving to a multi-year high. This powered stocks in the sector, with APA Corp. (NASDAQ:APA), Pioneer Natural Resources (NYSE:PXD), Hess Corp. (NYSE:HES) and EOG R...
On Friday, ChemoCentryx Inc. ( NASDAQ:CCXI ) shares spiked nearly 70% after announcing the Food and Drug Administration (FDA) had approved avacopan for the treatment of ANCA vasculitis. Avacopan is an orally administered small-molecule C5a receptor antagonist, which selectively ...
The stock market posted mixed results on Friday morning, as investors continued to wrestle with countervailing factors in making their investment decisions. As of 11:45 a.m. EDT, the Nasdaq Composite (NASDAQINDEX: ^IXIC) was trailing other major benchmarks, falling about a quarter p...
Gainers: ChemoCentryx (NASDAQ:CCXI) +70%. Renren (NYSE:RENN) +48%. DatChat (NASDAQ:DATS) +32%. ReShape Lifesciences (NASDAQ:RSLS) +29%. Huadi International (NASDAQ:HUDI) +24%. Voyager (NASDAQ:VYGR) +22%. NextPlay Technologies (NASDAQ:NXTP) +21%. Tian Ruixiang (NASDAQ:TIRX) +20%. Lilium (NASDA...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s always a great day when a company finds a new way to treat an illness, especially when that illness is quite rare. ChemoCentryx (NASDAQ: CCXI ) holders are having a better day than most, with their po...
News, Short Squeeze, Breakout and More Instantly...
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX PR Newswire TAVNEOS ® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif. , Oct. 20, ...
-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS ® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR -- SAN CARLOS, Calif., Oct. 17,...
-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), tod...